Myelodysplastic syndrome with excess blasts-2
diseaseOn this page
Also known as MDS-EB-2RAEB-2RAEB-IIrefractory anaemia with excess blasts type 2
Summary
Myelodysplastic syndrome with excess blasts-2 (MONDO:0015041) is a disease and 12 clinical trials. Top therapeutic interventions include fludarabine phosphate, cladribine, and enasidenib. A subtype of myelodysplastic syndrome with excess blasts — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Clinical trials: 12
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myelodysplastic syndrome with excess blasts-2 |
| Mondo ID | MONDO:0015041 |
| Orphanet | 100020 |
| NCIT | C7168 |
| UMLS | C4704767 |
| MedGen | 1644740 |
| GARD | 0019738 |
| Is cancer (heuristic) | no |
Also known as: MDS-EB-2 · myelodysplastic syndrome with Excess blasts-2 · RAEB-2 · RAEB-II · refractory anaemia with excess blasts type 2
Disease family
This is a subtype of myelodysplastic syndrome with excess blasts. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › myeloid hemopathy › myelodysplastic syndrome › myelodysplastic syndrome with excess blasts › myelodysplastic syndrome with excess blasts-2
Related subtypes (1): myelodysplastic syndrome with excess blasts-1
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 12.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03839771 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy |
| NCT04027309 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
| NCT03850574 | PHASE1/PHASE2 | RECRUITING | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| NCT01858740 | PHASE2 | COMPLETED | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children |
| NCT02220985 | PHASE2 | COMPLETED | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD |
| NCT02756572 | PHASE2 | COMPLETED | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms |
| NCT03338348 | PHASE2 | COMPLETED | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 |
| NCT04526288 | PHASE2 | TERMINATED | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease |
| NCT06247917 | PHASE2 | UNKNOWN | Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS |
| NCT02530034 | PHASE1 | ACTIVE_NOT_RECRUITING | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies |
| NCT05703542 | PHASE1 | RECRUITING | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT00426205 | Not specified | COMPLETED | GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 3 |
| CLADRIBINE | 4 | 1 |
| ENASIDENIB | 4 | 1 |
| GILTERITINIB | 4 | 1 |
| IVOSIDENIB | 4 | 1 |
| MELPHALAN | 4 | 1 |
| MIDOSTAURIN | 4 | 1 |
| MITOXANTRONE HYDROCHLORIDE | 4 | 1 |
| VOSAROXIN | 3 | 1 |
| TUSPETINIB | 2 | 1 |
| HU8F4 | 1 | 1 |
| CHEMBL4790597 | 0 | 1 |
| CHEMBL5075192 | 0 | 1 |
| CHEMBL5173987 | 0 | 1 |
| CHEMBL5199540 | 0 | 1 |
| CHEMBL4776881 | 0 | 1 |